Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimal Duration of Clopidogrel After Implantation of Second-Generation Drug-Eluting Stents (OPTIMA-C)

NCT03056118 is registered in ClinicalTrials.gov with Gangnam Severance Hospital as lead sponsor.

NCT NCT03056118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03056118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimal Duration of Clopidogrel After Implantation of Second-Generation Drug-Eluting Stents (OPTIMA-C)
Lead sponsor
Gangnam Severance Hospital
Phase
Phase 4
Overall status
Completed
Start date
May 2, 2011
Completion date
September 7, 2015
Enrollment
1,368 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic heart disease